RBC Capital raised the firm’s price target on Ligand (LGND) to $185 from $155 and keeps an Outperform rating on the shares. The company’s Q2 revenue beat was driven by better-than-expected Royalty and Captisol performance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand Pharmaceuticals Reports Strong Q2 2025 Results
- Positive Outlook on Ligand Pharma: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- Ligand raises FY25 adjusted EPS view to $6.70-$7.00 from $6.00-$6.25
- Ligand reports Q2 adjusted EPS $1.60, consensus $1.42
- Orchestra BioMed secures over $111M in proceeds, committed capital